menu
    • menu
    [{"orgOrder":0,"company":"HAL Allergy","sponsor":"Ergomed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Purethal Birch","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase IV","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Ergomed","highestDevelopmentStatusID":"11","companyTruncated":"HAL Allergy \/ Ergomed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Purethal Birch","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Purethal Birch","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase IV","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Purethal Grasses","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase IV","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Ergomed | ClinCompetence Cologne GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Purethal Mites","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HAL Allergy \/ Ergomed | ClinCompetence Cologne GmbH","highestDevelopmentStatusID":"10","companyTruncated":"HAL Allergy \/ Ergomed | ClinCompetence Cologne GmbH"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Purethal Mites","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"Sublivac Fix Phleum Prat","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Sublivac Fix Phleum Prat","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"HAL-MPE1","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"HAL-MPE1","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"HAL-MRE1","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Suspension","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HAL Allergy \/ Undisclosed"},{"orgOrder":0,"company":"HAL Allergy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Sublivac Fix Mite Mixture","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"HAL Allergy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Drops","sponsorNew":"HAL Allergy \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HAL Allergy \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by HAL Allergy

    Menu

    HAL Allergy

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Purethal Mites

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Ergomed | ClinCompetence Cologne GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mi...

                            Details : Purethal Mites is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dust Mite Allergy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 10, 2025

                            Lead Product(s) : Purethal Mites

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Ergomed | ClinCompetence Cologne GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HAL-MRE1

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human

                            Details : HAL-MRE1 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rhinitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 29, 2018

                            Lead Product(s) : HAL-MRE1

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HAL-MPE1

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HAL-MPE1 Safety and Tolerability Study

                            Details : HAL-MPE1 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Peanut Hypersensitivity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 14, 2016

                            Lead Product(s) : HAL-MPE1

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sublivac Fix Phleum Prat

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy

                            Details : Sublivac Fix Phleum Prat is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 22, 2015

                            Lead Product(s) : Sublivac Fix Phleum Prat

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sublivac Fix Mite Mixture

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SUBLIVAC FIX Mite Mixture Dose Tolerability Study

                            Details : Sublivac Fix Mite Mixture is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Dust Mite Allergy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 26, 2015

                            Lead Product(s) : Sublivac Fix Mite Mixture

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Purethal Birch

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SUBLIVAC FIX Birch Phase III Short-term Efficacy

                            Details : Purethal Birch is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Birch Pollen-induced Allergic Rhinoconjunctivitis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 04, 2014

                            Lead Product(s) : Purethal Birch

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HAL-MPE1

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HAL-MPE1 First-in-human

                            Details : HAL-MPE1 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Peanut Hypersensitivity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 13, 2014

                            Lead Product(s) : HAL-MPE1

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Purethal Birch

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Ergomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PURETHAL Birch RUSH Study

                            Details : Purethal Birch is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rhinitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 08, 2013

                            Lead Product(s) : Purethal Birch

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Ergomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sublivac Fix Phleum Prat

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SUBLIVAC FIX Phleum Pratense DT/DRF

                            Details : Sublivac Fix Phleum Prat is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 10, 2012

                            Lead Product(s) : Sublivac Fix Phleum Prat

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            HAL Allergy

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Purethal Birch

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding

                            Details : Purethal Birch is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 13, 2012

                            Lead Product(s) : Purethal Birch

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth